Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
JDM
MCID: CHL028
MIFTS: 59

Childhood Type Dermatomyositis (JDM)

Categories: Blood diseases, Bone diseases, Muscle diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Respiratory diseases, Skin diseases
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Childhood Type Dermatomyositis

About this section

MalaCards integrated aliases for Childhood Type Dermatomyositis:

Name: Childhood Type Dermatomyositis 38 12 15
Juvenile Dermatomyositis 12 76 53 59 73
Dermatomyositis, Childhood Type 73
Childhood Dermatomyositis 12
Juvenile Myositis 53
Juvenile Dm 59
Jdm 53
Jpm 53

Characteristics:

Orphanet epidemiological data:

59
juvenile dermatomyositis
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Worldwide); Age of onset: Adolescent,Childhood,Infancy; Age of death: normal life expectancy;

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Neuronal diseases Nephrological diseases Respiratory diseases Bone diseases Skin diseases Muscle diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 33 34
Orphanet: 59  
Rare neurological diseases
Rare renal diseases
Rare respiratory diseases
Rare systemic and rhumatological diseases
Rare skin diseases


Sources

Summaries for Childhood Type Dermatomyositis

About this section
NIH Rare Diseases : 53 Juvenile dermatomyositis has some similarities to adult dermatomyositis and polymyositis. It typically affects children ages 2 to 15 years, with symptoms that include weakness of the muscles close to the trunk of the body, inflammation, edema, muscle pain, fatigue, skin rashes, abdominal pain, fever, and contractures. Children with juvenile dermatomyositis may have difficulty swallowing and breathing, and the heart may also be affected.  About 20 to 30 percent of children with juvenile dermatomyositis develop calcium deposits in the soft tissue. Affected children may not show higher than normal levels of the muscle enzyme creatine kinase in their blood but have higher than normal levels of other muscle enzymes. Treatment is aimed at addressing the individual symptoms of each patient. This may involve a combination of medications, physical therapy and supplements.

MalaCards based summary : Childhood Type Dermatomyositis, also known as juvenile dermatomyositis, is related to arthritis and myositis. An important gene associated with Childhood Type Dermatomyositis is DMBX1 (Diencephalon/Mesencephalon Homeobox 1). The drugs Abatacept and Immunologic Factors have been mentioned in the context of this disorder. Affiliated tissues include skeletal muscle, skin and heart, and related phenotypes are muscular hypotonia and dysarthria

Wikipedia : 76 Juvenile dermatomyositis (JDM) is an idiopathic inflammatory myopathy (IMM) of presumed autoimmune... more...

Sources

Related Diseases for Childhood Type Dermatomyositis

About this section

Diseases related to Childhood Type Dermatomyositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 87)
# Related Disease Score Top Affiliating Genes
1 arthritis 10.4
2 myositis 10.4
3 juvenile overlap myositis 10.3
4 polymyositis 10.3
5 lung disease 10.3
6 interstitial lung disease 10.2
7 systemic lupus erythematosus 10.2
8 lupus erythematosus 10.2
9 vasculitis 10.2
10 idiopathic inflammatory myopathy 10.2
11 panniculitis 10.1
12 enthesopathy 10.1
13 autoimmune disease of gastrointestinal tract 10.0 HLA-DQA1 TNFRSF25
14 chilblain lupus 1 10.0 IFIH1 TNFRSF25
15 rheumatoid arthritis 10.0
16 hypertrichosis 10.0
17 pneumonia 10.0
18 juvenile rheumatoid arthritis 10.0
19 macrophage activation syndrome 10.0
20 type 1 diabetes mellitus 17 10.0 TNFRSF25 VWF
21 diabetes mellitus, insulin-dependent 10.0 HLA-DQA1 IFIH1 TNFRSF25
22 dermatomyositis 10.0
23 autoimmune disease 9.9
24 celiac disease 1 9.9
25 skin disease 9.9
26 lymphoma 9.9
27 capillary leak syndrome 9.9
28 rheumatic disease 9.9
29 dermatitis 9.9
30 psoriasis 9.9
31 systemic capillary leak syndrome 9.9
32 muscular disease 9.9 IFIH1 MORC3 NT5C1A
33 takayasu arteritis 9.8 HLA-DQA1 VWF
34 inclusion body myositis 9.8
35 nevus, epidermal 9.8
36 pneumothorax, primary spontaneous 9.8
37 digeorge syndrome 9.8
38 muscular dystrophy, duchenne type 9.8
39 autoimmune disease 1 9.8
40 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.8
41 lipedema 9.8
42 complement component 4a deficiency 9.8
43 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 9.8
44 diabetes mellitus 9.8
45 hematopoietic stem cell transplantation 9.8
46 hemolytic anemia 9.8
47 hepatitis 9.8
48 ulcerative colitis 9.8
49 colitis 9.8
50 thrombosis 9.8

Graphical network of the top 20 diseases related to Childhood Type Dermatomyositis:



Diseases related to Childhood Type Dermatomyositis
Sources

Symptoms & Phenotypes for Childhood Type Dermatomyositis

About this section

Human phenotypes related to Childhood Type Dermatomyositis:

59 32 (show all 45)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 muscular hypotonia 59 32 frequent (33%) Frequent (79-30%) HP:0001252
2 dysarthria 59 32 occasional (7.5%) Occasional (29-5%) HP:0001260
3 muscle weakness 59 32 hallmark (90%) Very frequent (99-80%) HP:0001324
4 dysphonia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001618
5 dysphagia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002015
6 constipation 59 32 frequent (33%) Frequent (79-30%) HP:0002019
7 arthritis 59 32 frequent (33%) Frequent (79-30%) HP:0001369
8 fever 59 32 frequent (33%) Frequent (79-30%) HP:0001945
9 fatigue 59 32 hallmark (90%) Very frequent (99-80%) HP:0012378
10 pulmonary fibrosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0002206
11 arthralgia 59 32 frequent (33%) Frequent (79-30%) HP:0002829
12 dyspnea 59 32 occasional (7.5%) Occasional (29-5%) HP:0002094
13 elevated serum creatine phosphokinase 59 32 hallmark (90%) Very frequent (99-80%) HP:0003236
14 emg abnormality 59 32 occasional (7.5%) Occasional (29-5%) HP:0003457
15 arrhythmia 59 32 occasional (7.5%) Occasional (29-5%) HP:0011675
16 angina pectoris 59 32 occasional (7.5%) Occasional (29-5%) HP:0001681
17 abdominal pain 59 32 occasional (7.5%) Occasional (29-5%) HP:0002027
18 pruritus 59 32 frequent (33%) Frequent (79-30%) HP:0000989
19 weight loss 59 32 occasional (7.5%) Occasional (29-5%) HP:0001824
20 limitation of joint mobility 59 32 occasional (7.5%) Occasional (29-5%) HP:0001376
21 dry skin 59 32 hallmark (90%) Very frequent (99-80%) HP:0000958
22 alopecia 59 32 frequent (33%) Frequent (79-30%) HP:0001596
23 autoimmunity 59 32 hallmark (90%) Very frequent (99-80%) HP:0002960
24 cardiomyopathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0001638
25 skin ulcer 59 32 frequent (33%) Frequent (79-30%) HP:0200042
26 myalgia 59 32 hallmark (90%) Very frequent (99-80%) HP:0003326
27 palpebral edema 59 32 hallmark (90%) Very frequent (99-80%) HP:0100540
28 bundle branch block 59 32 occasional (7.5%) Occasional (29-5%) HP:0011710
29 mucosal telangiectasiae 59 32 hallmark (90%) Very frequent (99-80%) HP:0100579
30 telangiectasia of the skin 59 32 hallmark (90%) Very frequent (99-80%) HP:0100585
31 muscle cramps 59 32 frequent (33%) Frequent (79-30%) HP:0003394
32 gastrointestinal hemorrhage 59 32 occasional (7.5%) Occasional (29-5%) HP:0002239
33 erythema 59 32 hallmark (90%) Very frequent (99-80%) HP:0010783
34 pericarditis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001701
35 skin rash 59 32 hallmark (90%) Very frequent (99-80%) HP:0000988
36 cough 59 32 occasional (7.5%) Occasional (29-5%) HP:0012735
37 vasculitis 59 32 frequent (33%) Frequent (79-30%) HP:0002633
38 hoarse voice 59 32 occasional (7.5%) Occasional (29-5%) HP:0001609
39 cutaneous photosensitivity 59 32 frequent (33%) Frequent (79-30%) HP:0000992
40 elevated c-reactive protein level 59 32 hallmark (90%) Very frequent (99-80%) HP:0011227
41 myositis 59 32 hallmark (90%) Very frequent (99-80%) HP:0100614
42 restrictive ventilatory defect 59 32 frequent (33%) Frequent (79-30%) HP:0002091
43 elevated erythrocyte sedimentation rate 59 32 hallmark (90%) Very frequent (99-80%) HP:0003565
44 poikiloderma 59 32 frequent (33%) Frequent (79-30%) HP:0001029
45 calcinosis 59 32 hallmark (90%) Very frequent (99-80%) HP:0003761
Sources

Drugs & Therapeutics for Childhood Type Dermatomyositis

About this section

Drugs for Childhood Type Dermatomyositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 63)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Abatacept Approved Phase 4,Phase 3 332348-12-6 10237
2 Immunologic Factors Phase 4,Phase 3,Phase 2,Not Applicable
3 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
4 Antirheumatic Agents Phase 4,Phase 3,Phase 2
5 Hormones Phase 4,Phase 3,Phase 2
6 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
7 Hormone Antagonists Phase 4,Phase 3,Phase 2
8 Vaccines Phase 4,Not Applicable
9 beta-endorphin Phase 4
10 Melanocyte-Stimulating Hormones Phase 4
11 Adrenocorticotropic Hormone Phase 4
12
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
13
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 2 302-25-0
14
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
15
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
16
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
17
Methylprednisolone hemisuccinate Approved Phase 3,Phase 2 2921-57-5
18
Methotrexate Approved Phase 3,Phase 2 59-05-2, 1959-05-2 126941
19
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
20
leucovorin Approved Phase 3,Phase 2 58-05-9 6006 143
21
Alendronate Approved Phase 2, Phase 3 66376-36-1, 121268-17-5 2088
22
Etanercept Approved, Investigational Phase 2, Phase 3 185243-69-0
23
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
24
Prednisolone hemisuccinate Experimental Phase 3,Phase 2 2920-86-7
25 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
26 Methylprednisolone acetate Phase 3,Phase 2
27 Antineoplastic Agents, Hormonal Phase 3,Phase 2
28 Antimetabolites, Antineoplastic Phase 3,Phase 2
29 Calcineurin Inhibitors Phase 3
30 Prednisolone acetate Phase 3,Phase 2
31 Peripheral Nervous System Agents Phase 3,Phase 2
32 Vitamin B9 Phase 3,Phase 2
33 Cyclosporins Phase 3
34 Vitamin B Complex Phase 3,Phase 2
35 Anti-Inflammatory Agents Phase 3,Phase 2
36 Antifungal Agents Phase 3
37 Folate Phase 3,Phase 2
38 Gastrointestinal Agents Phase 3,Phase 2
39 Folic Acid Antagonists Phase 3,Phase 2
40 Neuroprotective Agents Phase 3,Phase 2
41 Antiemetics Phase 3,Phase 2
42 glucocorticoids Phase 3,Phase 2
43 Antimetabolites Phase 3,Phase 2
44 Autonomic Agents Phase 3,Phase 2
45 Protective Agents Phase 3,Phase 2
46 Anti-Infective Agents Phase 3,Phase 2
47 Dermatologic Agents Phase 3,Phase 2
48 Bone Density Conservation Agents Phase 2, Phase 3
49 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
50 Analgesics, Non-Narcotic Phase 2, Phase 3

Interventional clinical trials:

(show all 24)
# Name Status NCT ID Phase Drugs
1 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
2 Abatacept in Juvenile Dermatomyositis Recruiting NCT02594735 Phase 4 Abatacept
3 Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis Recruiting NCT02245841 Phase 4 H.P. Acthar Gel
4 Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis Unknown status NCT00323960 Phase 3 3 MPDN pulse + PDN;3 MPDN pulse + PDN + CSA;3 MPDN pulse + PDN + MTX
5 Alendronate Osteoporosis Study Completed NCT00277251 Phase 2, Phase 3 Alendronate
6 Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy Recruiting NCT02971683 Phase 3 Abatacept subcutaneous;Placebo
7 Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis Terminated NCT00035958 Phase 2, Phase 3 Prednisone;Methotrexate;Etanercept
8 Absorption of Corticosteroids in Children With Juvenile Dermatomyositis Completed NCT00004357 Phase 2 Methylprednisolone;Prednisolone
9 Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) Completed NCT00106184 Phase 2 Rituximab;Placebo
10 Topical Sodium Thiosulfate and Fractional Carbon Dioxide Laser in Treating Dermatomyositis Associated Calcinosis Completed NCT01572844 Phase 2 Sodium thiosulfate
11 Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Recruiting NCT03267277 Phase 2 Sodium Thiosulfate
12 Creatine Supplementation in Pediatric Rheumatology Unknown status NCT01217320 Not Applicable
13 The Effect of Creatine Supplementation on Muscle Function in Childhood Myositis Completed NCT02267005 Not Applicable
14 Studies on Abnormal Bone From Patients With Polyostotic Fibrous Dysplasia and McCune Albright Syndrome Completed NCT00001973
15 The CARRA Registry Completed NCT01697254
16 Steroid-Induced Osteoporosis in the Pediatric Population - Canadian Incidence Study Completed NCT01663129
17 Juvenile Dermatomyositis Recruiting NCT03433638
18 Incidence and Prevalence of Juvenile Dermatomyositis Recruiting NCT03432455
19 Adult and Juvenile Myositis Recruiting NCT00017914
20 Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID / CAPS, DIRA, CANDLE, SAVI, CRMO, Still's Disease, Behcet's Disease, and Other Undifferentiated Autoinflammatory Diseases) Recruiting NCT00059748
21 Environmental Risk Factors for the Anti-synthetase Syndrome Recruiting NCT01276470
22 Yellow Fever Vaccine in Patients With Rheumatic Diseases Recruiting NCT03430388 Not Applicable
23 Study of Families With Twins or Siblings Discordant for Rheumatic Disorders Recruiting NCT00055055
24 Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes No longer available NCT01724580 Baricitinib

Search NIH Clinical Center for Childhood Type Dermatomyositis

Sources

Genetic Tests for Childhood Type Dermatomyositis

About this section
Sources

Anatomical Context for Childhood Type Dermatomyositis

About this section

MalaCards organs/tissues related to Childhood Type Dermatomyositis:

41
Skeletal Muscle, Skin, Heart, Bone, Lung, T Cells, Thyroid
Sources

Publications for Childhood Type Dermatomyositis

About this section

Articles related to Childhood Type Dermatomyositis:

(show top 50) (show all 669)
# Title Authors Year
1
Extensive skin ulcers in a child with juvenile dermatomyositis. ( 29367373 )
2018
2
Current management of juvenile dermatomyositis in Germany and Austria: an online survey of pediatric rheumatologists and pediatric neurologists. ( 29925381 )
2018
3
Development of practice and consensus-based strategies including a treat-to-target approach for the management of moderate and severe juvenile dermatomyositis in Germany and Austria. ( 29940960 )
2018
4
The Association Between Nailfold Capillary Density and Pulmonary and Cardiac Involvement in Medium- to Long-standing Juvenile Dermatomyositis. ( 29953739 )
2018
5
Multiple target autoantigens on endothelial cells identified in juvenile dermatomyositis using proteomics. ( 29361142 )
2018
6
Efficacy and safety of cyclophosphamide treatment in severe juvenile dermatomyositis shown by marginal structural modelling. ( 29342499 )
2018
7
A Viral Polymyositis Masquerade: Life-Threatening Case of Juvenile Dermatomyositis Complicated by Systemic Capillary Leak Syndrome. ( 29720802 )
2018
8
Treatment With Rituximab in Juvenile Dermatomyositis: Effect on Calcinosis. ( 30054253 )
2018
9
Long-term follow-up of autologous hematopoietic stem cell transplantation for refractory juvenile dermatomyositis: a case-series study. ( 30458860 )
2018
10
Cardiorespiratory fitness in long-term juvenile dermatomyositis: a controlled, cross-sectional study of active/inactive disease. ( 30508195 )
2018
11
Juvenile dermatomyositis with IgA nephropathy: case-based review. ( 30552457 )
2018
12
Muscle Expression of Type I and Type II Interferons Is Increased in Juvenile Dermatomyositis and Related to Clinical and Histological Features. ( 30552836 )
2018
13
Introduction of a novel magnetic resonance imaging-based scoring system for assessing disease activity in children with juvenile dermatomyositis. ( 29901756 )
2018
14
CD19+CD24hiCD38hi B Cells Are Expanded in Juvenile Dermatomyositis and Exhibit a Pro-Inflammatory Phenotype After Activation Through Toll-Like Receptor 7 and Interferon-α. ( 29988398 )
2018
15
Features distinguishing clinically amyopathic juvenile dermatomyositis from juvenile dermatomyositis. ( 30016492 )
2018
16
Juvenile dermatomyositis forty years on: Case report. ( 30064892 )
2018
17
Increased Soluble Cytoplasmic Bcl-2 Protein Serum Levels and Expression and Decreased Fas Expression in Lymphocytes and Monocytes in Juvenile Dermatomyositis. ( 30068766 )
2018
18
Clinical significance of subcutaneous fat and fascial involvement in juvenile dermatomyositis. ( 30092673 )
2018
19
Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: Experience at a single center in Japan. ( 30092736 )
2018
20
Clinical signs and symptoms in a joint model of four disease activity parameters in juvenile dermatomyositis: a prospective, longitudinal, multicenter cohort study. ( 30111380 )
2018
21
Juvenile dermatomyositis: novel treatment approaches and outcomes. ( 30124602 )
2018
22
Expression of the OAS Gene Family Is Highly Modulated in Subjects Affected by Juvenile Dermatomyositis, Resembling an Immune Response to a dsRNA Virus Infection. ( 30227596 )
2018
23
Periorbital Edema as the Initial Sign of Juvenile Dermatomyositis. ( 30234551 )
2018
24
Update on the clinical management of juvenile dermatomyositis. ( 30308133 )
2018
25
Reply: A child with severe juvenile dermatomyositis treated with ruxolitinib. ( 30335129 )
2018
26
A child with severe juvenile dermatomyositis treated with ruxolitinib. ( 30335130 )
2018
27
Fashionably Late: A Case of Delayed Cutaneous Manifestations in Juvenile Dermatomyositis. ( 30344821 )
2018
28
Serum biomarkers of glucocorticoid response and safety in anti-neutrophil cytoplasmic antibody-associated vasculitis and juvenile dermatomyositis. ( 30352204 )
2018
29
The Vasculopathy of Juvenile Dermatomyositis. ( 30356795 )
2018
30
Pattern of myogenesis and vascular repair in early and advanced lesions of juvenile dermatomyositis. ( 30389421 )
2018
31
Inpatient burden of juvenile dermatomyositis among children in the United States. ( 30424778 )
2018
32
Dysregulated NK cell PLCγ2 signaling and activity in juvenile dermatomyositis. ( 30429375 )
2018
33
Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research. ( 29084729 )
2018
34
Predictors of changes in disease activity among children with juvenile dermatomyositis enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry. ( 29170979 )
2018
35
Development and Testing of a Hybrid Measure of Muscle Strength in Juvenile Dermatomyositis for Use in Routine Care. ( 29245175 )
2018
36
Cardiovascular and cerebrovascular comorbidities of juvenile dermatomyositis in US children: an analysis of the National Inpatient Sample. ( 29373707 )
2018
37
A Bayesian semiparametric Markov regression model for juvenile dermatomyositis. ( 29462840 )
2018
38
Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis. ( 29474663 )
2018
39
Koebner Phenomenon in Juvenile Dermatomyositis. ( 29496916 )
2018
40
Correction: 2016 American college of rheumatology/European league against rheumatism criteria for minimal moderate, and major clinical response in juvenile dermatomyositis. ( 29530915 )
2018
41
Scrotal and Penile Ulcer in Juvenile Dermatomyositis: An Unusual Occurrence. ( 29561468 )
2018
42
Advances in Juvenile Dermatomyositis: Myositis Specific Antibodies Aid in Understanding Disease Heterogeneity. ( 29576174 )
2018
43
Potential association of LMNA-associated generalized lipodystrophy with juvenile dermatomyositis. ( 29610677 )
2018
44
Innovative Research Design to Meet the Challenges of Clinical Trials for Juvenile Dermatomyositis. ( 29637406 )
2018
45
Inverse Gottron papules in juvenile dermatomyositis: an under recognized clinical entity. ( 29721695 )
2018
46
Expression of myxovirus-resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis. ( 29770465 )
2018
47
Medications received by patients with juvenile dermatomyositis. ( 29773230 )
2018
48
Assessment of Microvascular Abnormalities by Nailfold Capillaroscopy in Juvenile Dermatomyositis After Medium- to Long-Term Followup. ( 28805016 )
2018
49
Recurrence of juvenile dermatomyositis 8A years after remission. ( 28050594 )
2017
50
Juvenile dermatomyositis positive for anti-DNA mismatch repair enzyme antibodies. ( 28073708 )
2017
Sources

Variations for Childhood Type Dermatomyositis

About this section
Sources

Expression for Childhood Type Dermatomyositis

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Childhood Type Dermatomyositis patients vs. healthy controls: 35 (show all 35)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 IFIT3 interferon-induced protein with tetratricopeptide repeats 3 Skeletal Muscle + 5.58 0.000
2 ISG15 ISG15 ubiquitin-like modifier Skeletal Muscle + 5.25 0.000
3 XIST X inactive specific transcript (non-protein coding) Skeletal Muscle + 5.14 0.000
4 RSAD2 radical S-adenosyl methionine domain containing 2 Skeletal Muscle + 4.94 0.000
5 GBP1 guanylate binding protein 1, interferon-inducible Skeletal Muscle + 4.88 0.000
6 CMPK2 cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial Skeletal Muscle + 4.61 0.000
7 IFI44L interferon-induced protein 44-like Skeletal Muscle + 4.42 0.000
8 MX1 MX dynamin-like GTPase 1 Skeletal Muscle + 4.40 0.000
9 IFI44 interferon-induced protein 44 Skeletal Muscle + 4.34 0.000
10 IFIT2 interferon-induced protein with tetratricopeptide repeats 2 Skeletal Muscle + 3.96 0.000
11 IFI27 interferon, alpha-inducible protein 27 Skeletal Muscle + 3.86 0.000
12 CXCL11 chemokine (C-X-C motif) ligand 11 Skeletal Muscle + 3.67 0.000
13 RPS4Y1 ribosomal protein S4, Y-linked 1 Skeletal Muscle - 3.57 0.000
14 IFIT1 interferon-induced protein with tetratricopeptide repeats 1 Skeletal Muscle + 3.57 0.000
15 MYH3 myosin, heavy chain 3, skeletal muscle, embryonic Skeletal Muscle + 3.54 0.000
16 SAMHD1 SAM domain and HD domain 1 Skeletal Muscle + 3.52 0.000
17 XAF1 XIAP associated factor 1 Skeletal Muscle + 3.44 0.000
18 KLHDC7B kelch domain containing 7B Skeletal Muscle + 3.44 0.000
19 IFI6 interferon, alpha-inducible protein 6 Skeletal Muscle + 3.43 0.000
20 IFIH1 interferon induced with helicase C domain 1 Skeletal Muscle + 3.43 0.000
21 PARP12 poly (ADP-ribose) polymerase family, member 12 Skeletal Muscle + 3.41 0.000
22 IFI16 interferon, gamma-inducible protein 16 Skeletal Muscle + 3.40 0.000
23 PLSCR1 phospholipid scramblase 1 Skeletal Muscle + 3.37 0.000
24 STAT1 signal transducer and activator of transcription 1, 91kDa Skeletal Muscle + 3.37 0.000
25 PSMB8 proteasome subunit beta 8 Skeletal Muscle + 3.35 0.000
26 NNMT nicotinamide N-methyltransferase Skeletal Muscle + 3.31 0.000
27 TRIM22 tripartite motif containing 22 Skeletal Muscle + 3.27 0.000
28 DTX3L deltex 3 like, E3 ubiquitin ligase Skeletal Muscle + 3.23 0.000
29 EIF2AK2 eukaryotic translation initiation factor 2-alpha kinase 2 Skeletal Muscle + 3.14 0.000
30 IRF7 interferon regulatory factor 7 Skeletal Muscle + 3.13 0.000
31 OAS1 2'-5'-oligoadenylate synthetase 1, 40/46kDa Skeletal Muscle + 3.09 0.000
32 IFITM1 interferon induced transmembrane protein 1 Skeletal Muscle + 3.06 0.000
33 TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 Skeletal Muscle + 3.05 0.000
34 PARP9 poly (ADP-ribose) polymerase family, member 9 Skeletal Muscle + 3.05 0.000
35 POSTN periostin, osteoblast specific factor Skeletal Muscle + 3.03 0.000
Search GEO for disease gene expression data for Childhood Type Dermatomyositis.
Sources

Pathways for Childhood Type Dermatomyositis

About this section
Sources

GO Terms for Childhood Type Dermatomyositis

About this section

Biological processes related to Childhood Type Dermatomyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein sumoylation GO:0016925 8.62 IFIH1 SAE1

Molecular functions related to Childhood Type Dermatomyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 single-stranded RNA binding GO:0003727 8.62 IFIH1 SNRPC
Sources

Sources for Childhood Type Dermatomyositis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....